ADAM17 and neoplasm: Immunohistochemical stains of RB patient tumor sections revealed a moderate (13 out of 20, 65%) to high expression (4 out of 20, 20%) of ADAM17 in most of the tumors analyzed (Figure 1a), while three out of 20 (15%) tumors displayed negative for ADAM17.